Pharmaceuticals, Biotechnology and Life Sciences
Company attracts three experienced industry executives to lead preclinical and clinical development as well as finance and operations Company incorporates…
– KALYDECO® (ivacaftor) is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis…
– KALYDECO® (ivacaftor) is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis…
The Treatment of High and Very high riSk dyslipidaemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a…
The Treatment of High and Very high riSk dyslipidaemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a…
– Phase 1 clinical trials evaluating LVGN6051 second generation 4-1BB (CD137) agonist antibody and KEYTRUDA® (pembrolizumab) for the treatment of…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…
Cell-Easy, a start-up based in Toulouse specialized in stem cell therapy, has signed an agreement with the University Hospital Centre in Toulouse, and secured the authorization to open a pharmaceutical manufacturing plant dedicated to the production of stem cells – a first in France.
CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the closing of an expanded Series A financing that raised a total of $43.9 million
UbiVac has announced working with BMS on Phase Ib study to combine UbiVac’s DRibble® Platform Vaccine, DPV-001 with anti-OX40 (BMS-986178) and Opdivo (nivolumab) to test hypothesis that this combination will augment anticancer immunity in advanced triple negative breast cancer.